Social Media Ideas for Daiichi Sankyo

‘We think about it every day’: How Daiichi Sankyo’s R&D chief plans to stay ahead in the ADC game

John Tsai, M.D., is rounding out his global drug development resume. Immediately after landing at Daiichi Sankyo, the pharma veteran finds himself leading the R&D portion of th...

<![CDATA[The Origins of Nuvation Bio’s Deal with Daichii Sankyo for the Rights to Safusidenib in Japan]]>

Sang

Sang Anonymous (not verified) Thu, 06/25/2026 - 03:02 field_thread_url https://cafepharma.com/boards/threads/sang.673523/ board name...

How Daiichi Sankyo aims to become a top five oncology player by 2035

Discover Daiichi Sankyo's pipeline strategy, including how it aims to become a top-five global oncology company by 2035. The post How Daiichi Sankyo aims to become a top five oncol...

Japan's Eisai to pump $64m into UK plant to package injectable drugs

<![CDATA[Novartis Announces $105 Million Collaborative Agreement with Antares Therapeutics]]>

<![CDATA[Eli Lilly and Abbisko Announce Drug Development Collaboration]]>

Otsuka showcases kidney drug data; Pfizer cuts an AI deal

Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s alliance with Innovent paid early dividends and Axso...

<![CDATA[Novartis to Acquire Myricx Bio for $1.1 Billion]]>

AstraZeneca, Daiichi Drug Approved as New First-Line Therapy for Tough Type of Breast Cancer

Datroway landed its third FDA approval in the past 18 months, this time as a treatment for triple negative breast cancer. The antibody drug conjugate was developed under a broad co...

Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program

The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Bruk...

Kissei ordered to add warning over vasculitis drug after fatalities

Twenty patients who took Tavneos, a drug for blood vessel inflammation, later died after developing liver dysfunction.

Takeda and Insilico strike AI-led drug discovery deal worth up to $600m

Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test

The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy. 

Takeda Vows Appeal of $885M Jury Verdict in ‘Pay-for-Delay’ Antitrust Case

Pharmacies and wholesalers claimed Takeda Pharmaceutical delayed generic competition from entering the market, forcing them to overpay for a gastrointestinal drug. Takeda said the...

Suntory sees opportunity in the OTC medicine business

The drinks maker is acquiring Daiichi Sankyo Healthcare and already has a health foods subsidiary.

<![CDATA[FDA Issues CRL to Elevar Therpaeutics for Combination of Rivoceranib and Camrelizumab ]]>

<![CDATA[Pharmaceutical Executive Daily: Eli Lilly and Abbisko Announce Drug Development Collaboration]]>

Daiichi Life to arrange leveraged buyout loans in first for Japan life insurer

<![CDATA[EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval]]>

<![CDATA[Biogen Enters $1 Billion Agreement to Acquire RayThera Inc. ]]>

Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown

Takeda has won the battle of the TYK2 inhibitors, toppling Bristol Myers Squibb’s Sotyktu to strengthen its hand ahead of an anticipated plaque psoriasis launch next year.

CVS obesity drug deal puts Lilly on equal footing with Novo

The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk. 

Samsung Bioepis launches Ustekinumab biosimilar in Japan with Nipro

Samsung Bioepis announced Wednesday the launch of its Ustekinumab biosimilar in Japan, marking the company’s first product debut in the country under a partnership with NIPRO Corp....